Clinical Trial: STRIDE (durvalumab + Tremelimumab) with Lenvatinib Vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06880523) titled 'STRIDE (durvalumab + Tremelimumab) with Lenvatinib Vs STRIDE Alone in Unresectable Hepatocellular Carcinoma' on March 11.

Brief Summary: The purpose of this study is to compare the effects on participants' and liver cancer by adding a drug that is used on its own to treat this disease to a combination of two other drugs which is also used to treat liver cancer, compared to the two-drug combination alone.

Study Start Date: May 31

Study Type: INTERVENTIONAL

Condition: Hepatocellular Carcinoma

Intervention: DRUG: STRIDE (durvalumab + tremelimumab)

As first treatment

DRUG: Durvalumab

monotherapy every 4 weeks

DRUG: Lenvatinib...